Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance
Year: 2019
Type: review
Abstract: Heart failure (HF) is a rapidly growing global public health problem. Since HF results in high mortality and re-hospitalization, new effective treatments are desired. Although it remains controversial, omega 3 polyunsaturated fatty acids (n-3 PUFAs), such as the eicosapentaenoic acid and docosahexaenoic acid, have been widely recognized to have benefits for HF. In a large-scale clinical trial regarding secondary prevention of HF by n-3 PUFA (GISSI-HF trial), the supplementation of n-3 PUFA significantly reduced cardiovascular mortality and hospitalization. Other small clinical studies proposed that n-3 PUFA potentially suppresses the ventricular remodeling and myocardial fibrosis, which thereby improves the ventricular systolic and diastolic function both in ischemic and non-ischemic HF. Basic investigations have further supported our understanding regarding the cardioprotective mechanisms of n-3 PUFA against HF. In these reports, n-3 PUFA has protected hearts through (1) anti-inflammatory effects, (2) intervention of cardiac energy metabolism, (3) modification of cardiac ion channels, (4) improvement of vascular endothelial response, and (5) modulation of autonomic nervous system activity. To clarify the pros and cons of n-3 PUFA on HF, we summarized recent evidence regarding the beneficial effects of n-3 PUFA on HF both from the clinical and basic studies.
DOI: 10.3390/ijms20164025
Institutions: Hamamatsu University, Hamamatsu University School of Medicine
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Keywords: heart failure, omega-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, cardioprotection, ventricular remodeling, myocardial fibrosis, anti-inflammatory activity, myocardial energy metabolism, cardiac ion channels, endothelial function, autonomic nervous system, GISSI-HF trial, cardiovascular mortality, hospitalization
Open Access status: gold
Estimated APC paid: $1,824
OpenAlex ID: W2968977140
